Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext: IPN; ADR:
IPSEY) have presented a new set of data on biomarkers from the
previously concluded tasquinimod Phase II study in chemotherapy-naïve
metastatic castrate resistant prostate cancer (CRPC) at the scientific
congress ESMO (European Society for Medical Oncology) held in Vienna
September 28-October 2.
Dr Michael Carducci, Johns Hopkins Medical Institute, Baltimore, US,
presented on Saturday September 29 the poster "Tasquinimod mechanism
of action biomarkers: Correlation with PFS and survival in men with
metastatic castrate resistant prostate cancer treated in a randomized
phase 2 trial*".
The purpose of this analysis from the phase II trial was to investigate
the effects of tasquinimod on selected biomarkers to confirm preclinical
findings on the mechanism of action. The results support an effect of
tasquinimod on both immunomodulation and angiogenesis which positions
tasquinimod as a potentially unique therapeutic approach with a
mechanism of action that does not target the androgen receptor pathway.
The findings shall be further validated in the ongoing phase III
placebo-controlled study in men with bone-metastatic CRPC, which has
been adequately powered to detect an OS improvement .